Upcoming Immuno-Oncology Congress to Provide New Insights, Panel Debates, Latest Research

Upcoming Immuno-Oncology Congress to Provide New Insights, Panel Debates, Latest Research

OGlogoThe 2016 Advances in Immuno-Oncology Congress will be at the Kensington Close Hotel in London, England, May 12-13, according to Oxford Global Conferences. In keeping with Oxford Global’s life sciences conference series, an expert panel of more than 30 speakers will present a full conference program.

Oxford Global notes that discovering new ways to effectively target and treat cancer is one of the most pressing challenges for the pharmaceutical industry today, with the immuno-oncology field currently predicted to reach a value totaling $25 billion annually by 2020.

The company notes that at this crucial time of growth and advancement, the Congress can provide invaluable insights into key technological and scientific innovations in the immuno-oncology field.


With the Congress speakers addressing the main challenges and opportunities in the industry, attending delegates will learn more about currently hot areas of research, including discovery of novel viral, antibody, and cell-based therapies, clinical partnerships and approaches to combination therapies.

The Congress’s first-day schedule will feature two topic streams. One will focus on discovery and early development issues for cancer immunotherapies, with presentations providing a comprehensive look at therapeutic strategies. An expert panel will discuss the latest advances in key therapeutic strategies in immuno-oncology, and attendees will have the opportunity to hear the latest on T-cell engineering, studies in B-cell biology, animal models, and toxicity issues.

Day One Stream 1 Topics:

  • Checkpoint inhibitors;
  • CAR T-cell therapies;
  • Adoptive cell transfer;
  • Cancer vaccines and oncolytic viral therapies;
  • Immune receptor agonist antibodies;
  • BiTe (Bispecific T-Cell Engagers);
  • Targeting the PD-1 pathway and finding alternative therapeutic targets;
  • Novel technologies to enhance discovery of immunotherapies in oncology;
  • Molecular oncology updates including B-cells.

The second stream on day one will cover clinical trials and later therapeutic approaches, including combination therapies and industry collaborations. Senior experts from biotech innovator organizations, as well as large pharma firms, will discuss their clinical data, address safety challenges in immuno-oncology development, and outline partnership opportunities. Speakers will also present the latest news on topics including clinical biomarker development.

Day One Stream 2 Topics:

  • Approaches to clinical trial design and development;
  • Key safety challenges in cancer immunotherapy clinical trials;
  • Strategies for effective trial management;
  • Clinical data and case studies;
  • Clinical immuno-oncology combinations in different cancers and tumor types;
  • Establishing partnerships and collaborations;
  • Biomarkers in immuno-oncology;
  • Clinical diagnostics and the potential of NGS in immuno-oncology clinical trials.

Day two of the Congress will focus on preclinical development, assays and modeling in immuno-oncology, covering topics that include preclinical biomarkers, trial design, and case studies of immunotherapies currently in late preclinical and early clinical stages.

Speakers will also discuss modeling with a focus on use of humanized mouse models. Presentations also include a discussions on preclinical combinations and in vivo imaging to evaluate biodistribution.

Day 2 Topics:

  • Preclinical models including humanized mouse models;
  • Preclinical assay development;
  • Translational strategies;
  • Approaches to preclinical combination therapy design;
  • Reducing toxicity challenges in immuno-oncology therapeutics;
  • Innovative technologies for immunotherapy.

The conference program consists of world-class keynote addresses, industry and academic-led presentations, panel debates, as well as ample networking opportunities, creating an interactive platform for high-level scientific and business discussion. Oxford Global says its speaker programs are carefully researched annually to ensure that delegates are exposed to the highest level of expertise.

For a sample, a webinar titled “Approaches to the Development Of Novel Cancer Immunotherapies,” with Marlon Hinner, director of immuno-oncology, Pieris Pharmaceuticals, is available for preview.

Oxford Global says use of immune-based treatments in oncology is increasingly becoming a central concern for the pharmaceutical industry, with ever more targets being discovered and new approaches being developed. From T-cell therapy to vaccines and antibody treatments, researchers are working toward more precise and effective immunotherapies. Hinner discusses key areas of development in work being done at Pieris.

Benefits of the webinar recording:

  • Advance your knowledge of cancer immunotherapy pitfalls and opportunities;
  • Learn from leading experts about their experiences in immunotherapy development;
  • Hear about different innovative approaches to cancer therapeutics and have the opportunity to pose your own questions to them.

The free webinar recording is for cancer immuno-oncology experts based in the European Union and the United States who are interested in hearing about challenges and successes in the development of cancer immunotherapies. You can download the recording here:

A list of speakers at the Congress can be found at:

Congress delegates benefit not only from the experience of the scheduled speakers, but also gain insight into the experiences of other attendees, with Q&A sessions and panel discussions that enable sharing of knowledge and facilitating the exchange of ideas.

This event is expected to attract more than 150 delegates representing leading biotech companies, global pharma organizations, and academic institutions, including senior-level decision-makers working at the forefront of the immuno-oncology industry in Europe and the U.S.

Information on prices can be found here:

Registration link.